Overview

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Prasugrel Hydrochloride